AIM: To study the effect of silymarin on the levels of tumor markers and MDA (malondialdehyde)-DNA adduct formation during N-nitrosodiethylamine induced hepatocellular carcinoma in male Wistar albino rats. METHODS: The levels of AFP, CEA and activities of liver marker enzymes in serum, MDA-DNA immunohistochemistry were done according to standard procedures in the control and experimental groups of rats. RESULTS: Hepatocellular carcinoma was evidenced from significant (p < 0.05) increases of alpha-fetoprotein, carcinoembryonic antigen, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, acid phosphatase, lactate dehydrogenase, gamma-glutamyltransferase and 5'-nucleotidase in serum and increased MDA-DNA adducts were also observed in the tissue sections of hepatocellular carcinoma. Silymarin treatment significantly attenuated the alteration of these markers and decreased the levels of MDA-DNA adduct formation. CONCLUSION: Silymarin could be developed as a promising chemotherapeutic adjuvant for the treatment of liver cancer.
AIM: To study the effect of silymarin on the levels of tumor markers and MDA (malondialdehyde)-DNA adduct formation during N-nitrosodiethylamine induced hepatocellular carcinoma in male Wistar albino rats. METHODS: The levels of AFP, CEA and activities of liver marker enzymes in serum, MDA-DNA immunohistochemistry were done according to standard procedures in the control and experimental groups of rats. RESULTS:Hepatocellular carcinoma was evidenced from significant (p < 0.05) increases of alpha-fetoprotein, carcinoembryonic antigen, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, acid phosphatase, lactate dehydrogenase, gamma-glutamyltransferase and 5'-nucleotidase in serum and increased MDA-DNA adducts were also observed in the tissue sections of hepatocellular carcinoma. Silymarin treatment significantly attenuated the alteration of these markers and decreased the levels of MDA-DNA adduct formation. CONCLUSION:Silymarin could be developed as a promising chemotherapeutic adjuvant for the treatment of liver cancer.
Authors: P Anandakumar; S Kamaraj; S Jagan; G Ramakrishnan; C Naveenkumar; S Asokkumar; T Devaki Journal: Mol Cell Biochem Date: 2009-05-18 Impact factor: 3.396
Authors: G Ramakrishnan; L Lo Muzio; C M Elinos-Báez; S Jagan; T A Augustine; S Kamaraj; P Anandakumar; T Devaki Journal: Cell Prolif Date: 2009-04 Impact factor: 6.831